Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Aytu Biopharma (AYTU) Liabilities from Discontinued Operations (2024)

Aytu Biopharma (AYTU) has disclosed Liabilities from Discontinued Operations for 1 consecutive years, with 557000.0 as the latest value for Q2 2024.

On a quarterly basis, Liabilities from Discontinued Operations changed N/A to 557000.0 in Q2 2024 year-over-year; TTM through Jun 2024 was 557000.0, a N/A change, with the full-year FY2024 number at 557000.0, changed N/A from a year prior.
Liabilities from Discontinued Operations was 557000.0 for Q2 2024 at Aytu Biopharma.
In the past five years, Liabilities from Discontinued Operations ranged from a high of 557000.0 in Q2 2024 to a low of 557000.0 in Q2 2024.